Twenty-nine articles since February 2026 on CMC governance, board-level technical risk, and the math of therapies reaching patients.
A structured ranking of biotech investors by activity, stage, and modality — the same capital intelligence we run inside engagements, made public.
That CMC, Quality, and Technical Operations leadership is the most underpriced variable on a biopharma board — and the fastest lever on whether a therapy reaches the people waiting for it.
Everything here points back to one published model: the CTO Mandate Framework — how boards should evaluate CMC and Quality leadership against company stage.
